Mitochondrial respiratory chain activity in the brain of young male rats subjected to alloxan-induced diabetes and a ketamine-induced schizophrenia-like model.
Patricia Gomes Wessler, Gustavo Antunes Mastella, Katia Gress, Alexandra S Heylmann, Camila S Amarante, Louyse S Damázio, Eleonor J Soligo Junior, Pauline S Effting, Micaela R Quadra, João Pedro Veronezi Rohling, Emilio L Streck, Alexandra I Zugno
Journal of Psychiatric Research November 11, 2026 DOI: 10.1016/j.jpsychires.2026.11.026 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study (2 × 2 factorial design) Peer reviewed |
|---|---|
| Sample size | 16 |
| Population | Male Wistar rats, 23 days old at assignment, divided into four groups (n = 4 per group) |
| Interventions | Alloxan Ketamine |
| Dose | Alloxan 150 mg/kg (single i.p. injection); ketamine 25 mg/kg i.p. daily |
| Duration | Ketamine or saline administered daily from day 4 to day 10 |
| Measures | Activities of mitochondrial respiratory chain complexes I, II, II-III and IV |
| Topics | Ketamine Esketamine |
| Keywords | Alloxan Brain energy metabolism Mitochondrial respiratory chain Schizophrenia |
| Key findings | Alloxan-induced diabetes was associated with lower complex II-III activity in the hippocampus and striatum, and an alloxan × ketamine interaction was seen for hippocampal complex I, where alloxan and ketamine each increased activity versus controls but their combination did not. No significant effects were detected in the frontal cortex; the authors characterize the findings as exploratory and requiring replication. |
Abstract
Type 1 diabetes mellitus (T1D) and schizophrenia (SZ) have both been associated with impaired brain energy metabolism. We investigated whether alloxan-induced insulin-deficient diabetes modifies the effects of a ketamine-induced schizophrenia-like model on the activity of brain mitochondrial respiratory chain enzymes. Male Wistar rats (23 days old) were assigned to four groups in a 2 × 2 factorial design: Control, Alloxan, Ketamine, and Ketamine + Alloxan. Diabetes was induced by a single intraperitoneal (i.p.) injection of alloxan (150 mg/kg), and ketamine (25 mg/kg, i.p.) or saline was administered daily from day 4 to day 10. The activities of complexes I, II, II-III and IV were measured in tissue homogenates of the frontal cortex, hippocampus and striatum (n = 4 per group) and analyzed by two-way ANOVA, with correction for multiple testing across all outcomes. No observation was excluded from any analysis. Three effects remained significant after correction for multiple testing: alloxan was associated with lower complex II-III activity in the hippocampus (q = 0.016) and striatum (q = 0.016), and an alloxan × ketamine interaction was observed for complex I in the hippocampus (q = 0.016), where alloxan and ketamine each increased activity compared with controls whereas their combination did not. Before correction, ketamine was also associated with higher complex II activity in the hippocampus (p = 0.006) and interactions were detected for complex II-III (p = 0.046) and complex IV (p = 0.019) in the hippocampus and for complex I in the striatum (p = 0.031); these uncorrected findings should be regarded as exploratory. No significant effect of alloxan, ketamine or their interaction was detected for any enzyme in the frontal cortex. In this exploratory study, alloxan-induced diabetes and ketamine were associated with region- and enzyme-specific differences in respiratory chain enzyme activity in the hippocampus and striatum, with alloxan attenuating some ketamine-associated increases. These findings require replication in adequately powered studies including both sexes and complementary measures of mitochondrial function.
Comparable studies
Other preclinical and animal studies on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Rats | 2010 | Observational study | |
| Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Conscious rats | 1997 | Dose-response study with microdialysis and behavioral testing | |
| NMDAR inhibition-independent antidepressant actions of ketamine metabolites Mice | 2016 | Preclinical study | |
| The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate Spinal neurons in decerebrate or pentobarbitone-anaesthetized cats and rats | 1983 | Experimental study | |
| R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects Mice | 2015 | Experimental study |